Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special PopulationsRelease Date:Research Inflammation & Immunology China Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) PathogensRelease Date:Research Inflammation & Immunology China Initiatives to Improve the Clinical Environment for Dermatologic Immunology, Inflammation, and Allergy CareRelease Date:Partner: The Japanese Society for Cutaneous Immunology and AllergyQuality Improvement Inflammation & Immunology Japan Real World, Long-term Efficacy Study of Ritlecitinib in Adult and Adolescent Patients with Severe Alopecia Areata in ChinaRelease Date:Research Inflammation & Immunology China Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UKRelease Date:Research Internal Medicine United Kingdom Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)Education Oncology All Quality Improvement Solutions for the Diagnosis and Management of Migraine and Headache DisordersQuality Improvement Internal Medicine Canada, USA Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease China Real-World Atopic Dermatitis: Italian Insights GrantRelease Date:Research Inflammation & Immunology Italy Title Grant Type Focus Area Country Application Due Date Innovative Digital Health Projects to increase the Quality of Life (QoL) of Multiple Myeloma (MM) patientsRelease Date:Quality Improvement Oncology Italy 2024 RD Global Monitoring anti-TFPI RESRelease Date:Research Rare Disease All Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)Education Oncology All Health Services Research to Improve Management of mBC Patients Treated with TucatinibRelease Date:Research Oncology All Addressing Multiple Myeloma Gaps in Care for Patients in Latin AmericaRelease Date:Partner: International Myeloma FoundationEducation Oncology Argentina, Brazil, Colombia, Mexico Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Management of Atopic Dermatitis / Alopecia AreataRelease Date:Education Inflammation & Immunology USA Improving the Care Process for Patients with Advanced Prostate CancerRelease Date:Partner: The American Urological Association Education and Research, Inc.; AstellasQuality Improvement Oncology USA Optimizing Care for patients with locally advanced or metastatic Urothelial Carcinoma (la/mUC)Release Date:Quality Improvement Oncology Canada Prospective Surveillance and Burden of Disease for RSV-Related Respiratory Tract Infections in Taiwanese Pediatric PopulationRelease Date:Research Vaccines Taiwan PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate CancerRelease Date:Education Oncology Canada Developing Educational Initiatives for ALK+ Metastatic Non-small Cell Lung Cancer Tyrosine Kinase Inhibitors TherapyRelease Date:Education Oncology Canada